19 Sep 2025 CNE is accelerating its transition to sustainable new energy business and prioritizing renewable energy initiatives, with the plan to gradually scaling back its green construction operations and other non-core businesses. Since 2022, the Group has invested in
18 Sep 2025 Sunny Optical’s 1H25 revenue was up by 4.2% YoY to Rmb19.65bn, driven by i) 1.7% YoY increase in handset segment (HLS/HCM) to Rmb13.2bn on better product mix with higher ASP; ii) 18.2% YoY increase in vehicle segment
12 September 2025 Q-Tech’s CCM and FPM shipment maintained strong momentum in 8M25. Total sales vol. of CCM increased 18.4% MoM/ 44.3% YoY to 47.1m units in 8M25. The strong YoY increase was primarily driven by the company’s expanded market
12 Sep 2025 Anta’s 1H25 revenue was up by 14.3% YoY to Rmb38.54bn, mainly driven by i) 5.4% YoY growth from core brand sales to Rmb16.95bn as a result of online growth, product enhancement and better store positioning; ii) 8.6%
3 September 2025 In 1H25, the global economic recovery remained sluggish, weighed down by persistent geopolitical tensions and rising trade protectionism which continued to cloud the growth outlook. China’s economy on the other hand began to show renewed resilience following
1 September 2025 Wasion’s 1H25 turnover increased by 17.3% YoY to Rmb4.4bn, while NP grew by 32.8% YoY to Rmb439.6m. In 1H25, sales of Wasion’s power AMI/ communication and fluid (C&F) AMI/ ADO, all recorded growth of 29.8%/12.8%/6.1% to Rmb1.9bn/
21 Aug 2025 Xtep’s 1H25 revenue was up by 7.1% YoY to Rmb6,838m, mainly driven by i) 4.5% YoY growth from core brand sales to Rmb6,053m as a result of the robust growth in online channels and increase in footwear
20 Aug 2025 TK Group’s (TKG) 1H25 revenue amounted to HK$1.1bn, representing a YoY increase of 4.3%, while NP also went up by 8.8% YoY to HK$86.8m. The mold fabrication segment delivered robust growth in 1H25, by registering 30.4% YoY
18 Aug 2025 OrbusNeich is a global medical device company focused on interventional technologies for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) has announced its 1H25 results. In 1H25, the company faced considerable challenges stemming from a complex
18 Aug 2025 CNE’s 1H25 revenue was down by 6.6% YoY to Rmb1,400m, mainly due to a 2.1% YoY decline in power sales to Rmb1,335m, which accounted for 95.4% of total revenue (1H24: 91.0%), and also a 52% YoY decrease
